Medincell

UZEDY® keeps building strong momentum 📈 Q1 2026 U.S. net sales reached $63M: +62% YoY and +15% vs Q4 2025, as adoption continues to accelerate. A great example of long‑term value creation through partnership. 🔗 lnkd.in/eC2ufG8J #Medincell #Teva #UZEDY #MentalHealth

🎥 Want to learn how formulation turns science into long-acting treatments? Watch full episode here: youtu.be/doveLSP7tic?si…

𝗪𝗵𝗮𝘁 𝗺𝗮𝗸𝗲𝘀 𝗮 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝘀𝘁 𝗳𝗼𝗿 𝘄𝗲𝗲𝗸𝘀 - 𝗼𝗿 𝗲𝘃𝗲𝗻 𝗺𝗼𝗻𝘁𝗵𝘀? In the first episode of 𝘐𝘯𝘴𝘪𝘥𝘦 𝘔𝘦𝘥𝘪𝘯𝘤𝘦𝘭𝘭, Emma Sergo takes us behind the science of formulation. 🎥Full video in comment👇 #Innovation #Biotech #InnovativeTreatments

Medincell expands its transatlantic analyst coverage: 🇺🇸 Leerink Partners - Outperform, €33 PT 🇪🇺 Degroof Petercam - Buy, €39 PT Strengthening our visibility accross global capital markets. 🔗 lnkd.in/ebxyvYEu #Medincell #Biotech #CapitalMarkets

How does long-acting #innovation translate into real patient impact? Join our live R&D Day on May 12 to explore our LAI technologies, pipeline strategy & partnerhsip model. 🔗🎥Access Live & save event to calendar >> medincell.com/rd-day-may-202… #Liveevent #Longactinginjectables

A new year, a bold #ShiftToGrowth 🚀 Our 135+ Medincell teammates from 25+ nationalities gathered in Montpellier to align on strategy, LAI innovation, and our growth ambition - then wrapped it up with teamwork on the golf course ⛳️ Excited for what’s next! #PurposefulInnovation

Advancing the next generation of Long‑Acting Injectables: Medincell will attend PBP World Meeting 2026 with Adolfo López-Noriega, Christophe Roberge & Anthony Rech. See visual for our talk & session times. #PBP2026 #Biopharmaceutics #LongActingInjectables #DrugDelivery

Medincell will be at #BIOEuropeSpring! James Gubbins, PhD, will be in Lisbon (Mar 23–25) to explore partnerships and present our BEPO® LAI technology. 🤝Want to meet? Contact James via the partnering platform. #BIO #BIOEurope #Biotech #Pharma #Partnering #BIOEuropeSpring2026

@MedinCell has raised €48M to advance key programs, boost our LAI platform, and strengthen future partnerships. Thank you to all supporting investors. 🔗 More details: medincell.com/successful-c-e…

📢 MedinCell HY Results Videoconference 🗓️ Dec 10, 2024 🇫🇷 6 PM CET (French): medincell.com/fr/live-fr 🇬🇧 7 PM CET (English): medincell.com/live-en Join us to hear our latest updates. #MedinCell #HYResults #CorporateEvent

Participez à notre Webinaire Recherche & Développement le jeudi 10 octobre à 18h00 Pour vous connecter : lnkd.in/eGdKnbAr Vous pouvez envoyer vos questions d'ordre scientifique et médical à communication@medincell.com, [Réunion en français]

📻 This morning, @christophedouat Douat was featured on @radioclassique , interviewed by @FrancoisGeff. It was a great opportunity to highlight the recent successes of Medincell and share what's coming next. 📢 Tune in to listen to the full interview here: smartlink.ausha.co/la-france-de-d…

@christophedouat Douat, CEO, and Richard Malamut, CMO, to present Medincell's portfolio and R&D pipeline at the Jefferies Global Healthcare Conference To access the presentation remotely, either live or on replay: wsw.com/webcast/jeff30… #JefferiesHealthcare

🌐✨ We are thrilled to unveil Medincell's new corporate website, designed to offer a more user-friendly, informative, and visually stunning online experience. This reflects our unwavering dedication to healthcare innovation. As Medincell embarks on a new era, this launch represents more than just a new website. It signifies a leap forward in how we connect, communicate, and collaborate, aiming to positively impact Global Health 🌍🌎🌏. Visit medincell.com #Medincell #HealthcareInnovation #GlobalHealth

Jefferies Initiates MedinCell’s Coverage with a “Buy” Recommendation Jefferies, one of the world’s leading international full-service investment banking and capital markets firms has initiated coverage of Medincell.  Jefferies analysts initiated coverage with a "Buy" rating and price target of €12, marking a +74% potential increase from yesterday market close. They wrote: “We view Medincell as the best positioned long acting injectables players, underpinned by best-in-class drug delivery technology, which should see it outperform competitors in growing blockbuster indications.” Read the press release: lnkd.in/eWGTmg-m

Follow our half-year earnings call, today at 6:30pm CET > To watch the meeting in French: #events_" target="_blank" rel="nofollow noopener">medincell.com/fr/investisseu… > To watch the meeting in English: #events_" target="_blank" rel="nofollow noopener">medincell.com/en/investors/#…

🚀 MedinCell applauds @TevaUSA and @RoyaltyPharma collaboration to further accelerate olanzapine LAI program (mdc-TJK), an innovative approach to schizophrenia treatment. 💡 Investment in Innovation Teva has secured an investment of up to $125M from Royalty Pharma to advance mdc-TJK, a therapy with the potential to be the first of its kind for schizophrenia. Ongoing Phase 3 trial results are now expected earlier than anticipated in the second half of 2024. 🤝 Confidence in Progress The renowned expertise and robust track record of Royalty Pharma lend substantial confidence to the value and transformative potential of mdc-TJK. 🔍 Commitment to Care Great to witness Teva's commitment to accelerating the development of this promising therapy, which could significantly impact the lives of patients with schizophrenia. For more information on this promising development: Teva’s Press Release: lnkd.in/e4XBCBxS MedinCell’s Press Release: lnkd.in/eSkUMwCu #MedinCell #TevaPharmaceuticals #RoyaltyPharma #MentalHealthInnovation #SchizophreniaCare

📌 Save the Date! Join MedinCell's CEO Christophe Douat & CMO Richard Malamut at the Jefferies London Healthcare Conference. 🗓️ Nov 16, 1:30pm GMT 🔗 Tune in live or watch the replay: wsw.com/webcast/jeff28… Excited to showcase our latest in #HealthcareInnovation. Stay tuned! #JefferiesConference

🔬 Exciting News! This week, The @TheLancetPsych publishes the results from the Phase 3 RISE study of UZEDY, championed by our partner @TevaUSA Pharmaceuticals. Study findings played a pivotal role in securing FDA approval for UZEDY in April 2023, marking a new step in treating schizophrenia in adults through a convenient subcutaneous injection every 1-2 months. 🌟 What makes UZEDY stand out? It's the pioneering product harnessing the power of MedinCell BEPO technology, licensed to TEVA as SteadyTeq, bringing innovative treatment options to our patients. 📖 Dive into the detailed RISE study findings: lnkd.in/eE_iB2tr

RT @LePointEvents: J-1 ! 📣 Tenez-vous prêts… pour #FuturapolisSanté 2023 ! Sortez vos cahiers et stylos ! 📝 #Conférences captivantes, #at…